<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Roks, G.</title>
    <link>http://repub.eur.nl/res/aut/6087/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Creutzfeldt-Jakob disease 38 years after diagnostic use of human growth hormone (Article)</title>
      <link>http://repub.eur.nl/res/pub/5880/</link>
      <pubDate>2002-06-05T00:00:00Z</pubDate>
      <description>A 47 year old man is described who developed pathology proven Creutzfeldt-Jakob disease (CJD) 38 years after receiving a low dose of human derived growth hormone (hGH) as part of a diagnostic procedure. The patient presented with a cerebellar syndrome, which is compatible with iatrogenic CJD. This is the longest incubation period described so far for iatrogenic CJD. Furthermore, this is the first report of CJD after diagnostic use of hGH. Since the patient was one of the first in the world to receive hGH, other cases of iatrogenic CJD can be expected in the coming years.</description>
    </item> <item>
      <title>Apolipoprotein E4 in the temporal variant of frontotemporal dementia (Letter To Editor)</title>
      <link>http://repub.eur.nl/res/pub/5888/</link>
      <pubDate>2002-06-05T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Amyloid beta secretase gene (BACE) is neither mutated in nor associated with early-onset Alzheimer's disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/5851/</link>
      <pubDate>2001-11-02T00:00:00Z</pubDate>
      <description>The beta-site of beta-amyloid precursor protein cleaving enzyme (BACE) cleaves the beta-amyloid (Abeta) precursor protein at the N-terminal end of Abeta, allowing for the production of Abeta by C-terminal gamma-secretase cleavage. We hypothesized that over-activity of BACE might lead to the overproduction of Abeta, hence causing Alzheimer's disease (AD). Molecular genetic analyses of BACE in 9 autosomal dominant AD families and a population-based sample of 101 presenile AD cases did not identify genetic linkage, pathogenic mutations or genetic association with BACE, suggesting that BACE is not genetically involved in the etiology of AD</description>
    </item> <item>
      <title>Variable expression of presenilin 1 is not a major determinant of risk for late-onset Alzheimer's Disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/5852/</link>
      <pubDate>2001-11-01T00:00:00Z</pubDate>
      <description>We have previously reported a significant association between early-onset Alzheimer's disease (EOAD) and an allele in the promoter of presenilin 1 (PSEN1) significantly decreasing PSEN1 expression in vitro. For late-onset Alzheimer's disease (LOAD), numerous studies have reported inconsistent associations with a PSEN1 intronic polymorphism. We therefore hypothesized that linkage disequilibrium between the intronic PSEN1 polymorphism and the functional promoter polymorphism might explain the conflicting reports in LOAD. We analysed both variations in 356 LOAD patients and 230 controls in a population-based case-control study. In addition, we re-analysed all published literature on the PSEN1 intronic polymorphism in a meta-analysis. No significant association was found with the PSEN1 intronic or promoter polymorphism in our case-control sample. In the meta-analysis no major differences between patients and controls were found for the PSEN1 intronic variation. Together, our results do not support a major role for variable expression of PSEN1 in LOAD.</description>
    </item> <item>
      <title>The Cystatin C polymorphism is not associated with early-onset Alzheimer's disease. (Article)</title>
      <link>http://repub.eur.nl/res/pub/5854/</link>
      <pubDate>2001-01-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Mutation screening of the tau gene in patients with early-onset Alzheimer's disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/5838/</link>
      <pubDate>1999-12-24T00:00:00Z</pubDate>
      <description>Hyperphosphorylated microtubule associated protein tau, present in neurofibrillary tangles, is a prominent pathological feature of Alzheimer's disease (AD). The gene encoding tau (MAPT) was recently found mutated in frontotemporal dementia (FTD) and other tauopathies. We studied MAPT as a candidate gene in the etiology of AD. The study population consisted of 101 early-onset AD patients and 117 controls. Mutation analysis did not detect causal mutations in exons 9 to 13 encoding the microtubule-binding domains involved in FTD, however, two novel polymorphisms were detected in exon 9. Using the Ala169 polymorphism in exon 9 and a previously reported (CA)n-repeat polymorphism in intron 9, an association study was performed. No association with early-onset AD was detected. Together, our data indicate that MAPT does not play a role in early-onset AD.</description>
    </item> <item>
      <title>The -491 A/T polymorphism in the regulatory region of the apolipoprotein E gene and early-onset Alzheimer's disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/5830/</link>
      <pubDate>1998-12-18T00:00:00Z</pubDate>
      <description>The -491 polymorphism in the promoter region of the apolipoprotein E gene (APOE) has been suggested to be associated with increased risk for Alzheimer's disease (AD) independent of APOE status. We studied the association between the -491 polymorphism and risk for early-onset Alzheimer's disease in 99 Dutch and 78 Spanish patients. In patients with early-onset AD, we found no consistent relationship with a single allele of the -491 polymorphism. Linkage disequilibrium between the polymorphism and the APOE gene was found which most likely might explain the inconsistent findings.</description>
    </item>
  </channel>
</rss>